| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f9bbbd98f2eaed32adaf0748ad97147 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2012-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fe998f5e763d5d99c5f0519d6805e14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de45184d081852ec0ed00a17f8b6808f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08bc4583b4bd8c1276dd0d84a74fd540
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ba67f65aea6a4af411d45601da08228 |
| publicationDate |
2012-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2012249633-A |
| titleOfInvention |
How to predict the effect of sorafenib |
| abstract |
The present invention predicts in advance whether or not hepatocellular carcinoma patients and renal cell carcinoma patients have a significant effect on sorafenib, and enables appropriate administration of sorafenib to improve the therapeutic effect. Genomic DNA is extracted from a test sample and subjected to real-time quantitative PCR to detect FGF3 gene amplification. In this real-time quantitative PCR, it is determined as positive when amplification of the FGF3 gene has a copy number of 10 or more. [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015176178-A |
| priorityDate |
2011-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |